Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

CRISM Therapeutics Stock Gains Bullish Momentum as ChemoSeed Clinical Trial Advances Toward Patient Recruitment

CRISM Therapeutics Corporation is a UK clinical-stage drug-delivery company focused on improving the performance of established chemotherapy medicines through localized, sustained administration. Its ChemoSeed implant is designed to deliver a therapeutic agent directly into tumour tissue or a surgical resection margin. The recent share-price …

Ankur Sharma | 14 August 2026

ImmuPharma Shares Gain Momentum as Kapiglucagon Progress Revives Investor Optimism

ImmuPharma plc is a specialist biopharmaceutical developer focused on peptide-based treatments for autoimmune diseases, diabetes and serious infections. Its principal programmes include the P140 autoimmune platform, Kapiglucagon for Type One diabetes applications and early anti-infective candidates. The recent share-price rise appears connected to continuing …

Ankur Sharma | 14 August 2026

Oxford Nanopore Misses Again on China — Is the Genomics Disruptor Still Worth the Wait?

Oxford Nanopore (LSE:ONT) Technologies floated as one of the great hopes of British science: a home-grown genomics disruptor whose pocket-sized DNA sequencers promised to upend a market dominated by larger US rivals. Since then, investor patience has been repeatedly tested, and the group's 2026 …

Ankur Sharma | 14 August 2026

4basebio Stock Drops 9.09%: Are Investors Watching Clinical Revenue, Cash Resources and DNA Manufacturing Scale?

4basebio plc LSE:4BB is attracting attention after its shares declined9.09% on 13 August 2026.

Ankur Sharma | 13 August 2026

Could Futura Medical LSE:FUM Shares Be Facing Profit-Taking After Recent Eroxon and Pipeline Catalysts?

Futura Medical plc LSE:FUM is attracting significant attention after its shares dropped19.79% on 13 August 2026.

Ankur Sharma | 13 August 2026

Could Proteome Sciences LSE:PRM Shares Be Repricing Despite New Clinical Contracts and Stronger Chemoproteomics Demand?

Proteome Sciences plc LSE:PRM is attracting attention after its shares declined7.59% on 13 August 2026.

Ankur Sharma | 13 August 2026

Why Are Provexis Shares Falling 10.31% as Investors Reassess Fruitflow Growth and Commercial Momentum?

Provexis plc LSE:PXS is attracting attention after its shares fell10.31% on 13 August 2026, continuing the highly volatile trading pattern associated with the small-cap healthcare company.

Ankur Sharma | 13 August 2026

LSE:STX in focus: Why investors are watching Shield Therapeutics after strong H1 growth and new clinical progress

Shield Therapeutics plc LSE:STX is attracting renewed investor attention after its shares gained3.57% on 13 August 2026.

Ankur Sharma | 13 August 2026

Is CVS Group plc Building on Recent Gains?

Daily Change:+12.00p (up 0.93%) as of the latest session

Ishan Mudgal | 13 August 2026

Is Genus plc Building on Recent Gains?

Daily Change:+42.00p (up 1.86%) as of the latest session

Ishan Mudgal | 13 August 2026
Support

Hi! How can we help you today?

Loading…